title: Probiotics as efficient immunopotentiators: translational role in cancer prevention.
abstract: Accumulating evidences indicate that some diseases are triggered by abnormalities of the gut microbiota. Among these, immune-related diseases can be the promising targets for probiotcs. Several studies have proved the efficacy of probiotics for preventing such diseases including cancers, infections, allergies, inflammatory bowel diseases and autoimmune diseases. Lactobacillus casei strain Shirota (LcS) is one of the most popular probiotics, benefits of which in health maintenance and disease control have been supported by several science-based evidences. This review summarizes human clinical trials with this probiotic against cancer development and also discusses the possible immunomodulatory mechanisms by which LcS exerts anti-cancer activity.
authors.forename: Kan
authors.initials: K
authors.lastname: Shida
authors.affiliation: Yakult Central Institute for Microbiological Research, Tokyo, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Nomoto
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000276:immunology / Q000382:microbiology*; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology / Q000378:metabolism; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D007780:Lacticaseibacillus casei / Q000276:immunology; D064307:Microbiota / Q000187:drug effects / Q000276:immunology; D009369:Neoplasms / Q000473:pathology / Q000517:prevention & control*; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D018664:Interleukin-12